• Explore /
  • Poster
  • / An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).

An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).

Abstract Video & Slides Poster

Authors

Guru P. Sonpavde

Guru Sonpavde

Dana-Farber Cancer Institute, Boston, MA

Guru Sonpavde , Aurelien Marabelle , Yohann Loriot , Cora N. Sternberg , Jae-Lyun Lee , Aude Flechon , Guilhem Roubaud , Damien Pouessel , Vittorina Zagonel , Fabio Calabro , Giuseppe L. Banna , Sang Joon Shin , Francisco Emilio Vera Badillo , Thomas Powles , Eva Hellmis , Paulo Andre Palhares de Miranda , Ana Rita Lima , William Sawyer , Sebastien J. Hotte

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03084471

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 429)

DOI

10.1200/JCO.2021.39.6_suppl.429

Abstract #

429

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Guru Sonpavde

First Author: Marwan Fakih

Poster

2019 Gastrointestinal Cancers Symposium

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.

First Author: Yung-Jue Bang

First Author: Eileen Mary O'Reilly